Coherus Biosciences sells Cimerli, a Lucentis biosimilar, to SDZNY.

March 22, 2024 | by


Coherus Biosciences, a leading biotechnology company, has recently announced the sale of their highly anticipated Lucentis biosimilar, Cimerli, to SDZNY. This significant business move comes after the company’s successful phase 1 trial of their anti-CCR8 antibody, CHS-114, in solid tumors. Additionally, Coherus Biosciences reported impressive net revenue of $91.5M in Q4’23, showcasing their financial strength and potential. While the Cimerli sale could lead to lost revenues, the company’s Udenyca is expected to have a strong first quarter in 2024, effectively offsetting the potential impact. With their promising pipeline data and strategic initiatives, Coherus Biosciences continues to be rated as a strong buy within the industry, although risks such as underperformance in Q1’24 earnings and potential negative market reception remain present. The upcoming launch of Udenyca Onbody and the inclusion of Loqtorzi in the NCCN guidelines for NPC are expected to contribute to the company’s robust revenue growth.

Coherus Biosciences sells Cimerli, a Lucentis biosimilar, to SDZNY.

Coherus Biosciences sells Cimerli to SDZNY

Coherus Biosciences, a leading biopharmaceutical company, has announced the sale of Cimerli, a Lucentis biosimilar, to SDZNY. This strategic move aims to optimize Coherus Biosciences’ portfolio and streamline its focus on its core products and pipeline. The sale of Cimerli will have significant implications for both Coherus Biosciences and SDZNY.


Impact on Coherus Biosciences

The sale of Cimerli will undoubtedly have several effects on Coherus Biosciences. First and foremost, it will enable the company to reallocate resources and capital towards its core business activities. By divesting a non-core asset, Coherus Biosciences can concentrate on the development and commercialization of its innovative portfolio, enhancing its competitive position in the market.

Furthermore, the sale of Cimerli will have a financial impact on Coherus Biosciences. The company will receive a substantial amount of proceeds from the transaction, which can be utilized to support ongoing research and development efforts, as well as potential strategic acquisitions. This influx of capital will provide Coherus Biosciences with the necessary resources to advance its pipeline and drive future growth.


Coherus Biosciences sells Cimerli, a Lucentis biosimilar, to SDZNY.

Impact on SDZNY

For SDZNY, the acquisition of Cimerli represents an opportunity to expand its product portfolio and strengthen its position in the market. By adding a Lucentis biosimilar to its offerings, SDZNY can cater to a broader range of patient needs and potentially capture a larger market share. This strategic move aligns with SDZNY’s growth objectives and allows the company to tap into new revenue streams.


Additionally, the acquisition of Cimerli presents SDZNY with the potential for synergies and cost savings. By leveraging its existing infrastructure and distribution channels, SDZNY can efficiently commercialize Cimerli and maximize its market penetration. This strategic maneuver positions SDZNY for long-term success and empowers the company to provide innovative therapies to patients in need.

Promising results of Coherus Biosciences’ anti-IL-27 antibody

Coherus Biosciences’ anti-IL-27 antibody, casdozokitug, has recently shown promising results in the treatment of hepatocellular carcinoma (HCC). HCC is a common type of liver cancer with limited treatment options, making this breakthrough particularly significant.


Details of the anti-IL-27 antibody

Casdozokitug is a novel therapeutic agent that targets IL-27, a cytokine involved in various inflammatory processes. By blocking IL-27 signaling, casdozokitug can potentially suppress tumor growth and modulate the immune response against cancer cells.

Hepatocellular carcinoma response rate

In clinical trials, casdozokitug demonstrated an impressive overall response rate of 38% in patients with HCC. This means that a significant proportion of patients experienced a reduction in tumor size or stabilization of the disease, indicating the potential of casdozokitug as an effective treatment option for HCC.

Potential implications in cancer treatment

The promising results of casdozokitug in HCC have significant implications for cancer treatment as a whole. By targeting IL-27, casdozokitug offers a novel therapeutic approach that can complement existing treatment modalities, such as chemotherapy and targeted therapies. This antibody has the potential to improve patient outcomes and quality of life, presenting an exciting advancement in the field of oncology.

Coherus Biosciences sells Cimerli, a Lucentis biosimilar, to SDZNY.

Expectations for Udenyca

Udenyca, Coherus Biosciences’ biosimilar version of Neulasta, is expected to have a strong performance in the first quarter of 2024. This anticipation stems from several factors that position Udenyca for success and enable it to offset the lost revenues from the Cimerli sale.

Anticipated performance in Q1’24

Based on market analysis and demand projections, Udenyca is expected to continue its upward trajectory in terms of sales and market share. The biosimilar has already gained significant traction and acceptance in the market, driven by its comparable efficacy and cost-effectiveness. With a favorable reimbursement landscape and increasing adoption by healthcare providers, Udenyca is poised to deliver strong financial results in Q1’24.

Offsetting lost revenues from Cimerli sale

The sale of Cimerli may result in a temporary revenue gap for Coherus Biosciences. However, the anticipated strong performance of Udenyca can help offset this loss. Revenue generated by Udenyca in the first quarter of 2024 is projected to contribute significantly to Coherus Biosciences’ financial position, minimizing the impact of the Cimerli divestment on the company’s overall revenue.

Importance of Udenyca to Coherus Biosciences

Udenyca holds immense importance for Coherus Biosciences as a flagship biosimilar product. Its success not only brings in substantial revenue but also solidifies Coherus Biosciences’ position as a key player in the biosimilars market. Furthermore, the positive reception and growing demand for Udenyca underscore the company’s ability to develop and commercialize high-quality biosimilar products. This bolsters investor confidence and supports Coherus Biosciences’ long-term growth strategy.

Phase 1 trial of anti-CCR8 antibody CHS-114

Coherus Biosciences has recently completed a phase 1 trial for its anti-CCR8 antibody, known as CHS-114. This trial provided valuable insights into the potential applications of CHS-114 in the treatment of solid tumors.

Overview of the antibody

CHS-114 is an innovative therapeutic agent that targets CCR8, a chemokine receptor implicated in the progression and metastasis of various solid tumors. By blocking CCR8 signaling, CHS-114 has the potential to impede tumor growth and inhibit the spread of cancer cells.

Data from the phase 1 trial

The phase 1 trial for CHS-114 demonstrated encouraging results, indicating its potential efficacy and safety in patients with solid tumors. The trial evaluated the optimal dosage, administration schedule, and overall tolerability of CHS-114. Early data suggests that CHS-114 shows promise in terms of inhibiting tumor growth and inducing positive clinical responses.

Potential applications in solid tumor treatment

The data from the phase 1 trial of CHS-114 opens up exciting possibilities for the treatment of solid tumors. By targeting CCR8, CHS-114 offers a novel therapeutic approach that can complement existing treatment modalities, such as surgery, chemotherapy, and radiation therapy. The development of CHS-114 represents a significant advancement in the field of oncology and has the potential to improve patient outcomes in the future.

Coherus Biosciences sells Cimerli, a Lucentis biosimilar, to SDZNY.

Financial update of Coherus Biosciences

Coherus Biosciences has reported a strong financial performance for the fourth quarter of 2023, reflecting the company’s robust business strategies and market presence. Several key financial highlights underscore Coherus Biosciences’ growth trajectory and financial stability.

Q4’23 net revenue

In Q4’23, Coherus Biosciences recorded net revenue of $91.5 million, representing a significant increase compared to the previous quarter. This growth can be attributed to the successful commercialization of key products, such as Udenyca and Loqtorzi, as well as an expanding customer base. The strong revenue figures validate Coherus Biosciences’ market leadership and affirm the company’s ability to deliver value to its shareholders.

Prepayment of term loan

Coherus Biosciences has made the strategic decision to prepay $175 million of its term loan with Pharmakon Advisors LP. This prepayment is aimed at optimizing the company’s capital structure and reducing its long-term debt. By deleveraging its balance sheet, Coherus Biosciences enhances its financial flexibility and positions itself for future investments and strategic initiatives.

Partnership with Pharmakon Advisors LP

Coherus Biosciences’ partnership with Pharmakon Advisors LP demonstrates the company’s commitment to prudent financial management and capital optimization. This collaboration allows Coherus Biosciences to benefit from the expertise and resources of Pharmakon Advisors LP, ensuring a robust financial foundation and facilitating future growth opportunities.

Contributors to revenue growth

Coherus Biosciences has identified several key factors that have contributed to its revenue growth and market success. These factors encompass the launch of new products, collaborations with key stakeholders, and recognition by influential medical guidelines.

Launch of Udenyca Onbody

The launch of Udenyca Onbody, an innovative delivery system for Udenyca, has played a pivotal role in Coherus Biosciences’ revenue growth. This novel device enables patients to self-administer Udenyca conveniently, reducing the burden on healthcare providers and improving patient adherence. The successful implementation of Udenyca Onbody has expanded the market reach of Udenyca and propelled its commercial success.

Inclusion of Loqtorzi in NCCN guidelines

The inclusion of Coherus Biosciences’ product, Loqtorzi, in the National Comprehensive Cancer Network (NCCN) guidelines for neuroendocrine tumors (NETs) has significantly fueled revenue growth. This recognition by the NCCN validates the efficacy and safety of Loqtorzi, positioning it as a preferred treatment option for NETs. The endorsement by influential medical guidelines has bolstered the market acceptance and adoption of Loqtorzi, resulting in increased revenue for Coherus Biosciences.

Expected impact on revenue

The launch of Udenyca Onbody and the inclusion of Loqtorzi in the NCCN guidelines are expected to have a continued positive impact on Coherus Biosciences’ revenue growth. These key developments ensure the continued success of both Udenyca and Loqtorzi, driving market penetration and expanding patient access to these innovative therapies. Coherus Biosciences remains committed to leveraging its market-leading position and delivering sustainable revenue growth in the future.

Buy rating for Coherus Biosciences

Coherus Biosciences has received a buy rating based on its strong market position, financial performance, and promising pipeline data. Several factors contribute to this favorable rating, highlighting the company’s potential for long-term success and value creation.

Reasons for the buy rating

The buy rating for Coherus Biosciences stems from its robust business strategies, successful commercialization of key products, and a diversified pipeline of innovative therapies. The company’s ability to consistently deliver strong financial results, as evidenced by its revenue growth and market recognition, instills confidence in investors and analysts alike.

Ability to handle Cimerli revenue loss

Coherus Biosciences has demonstrated its ability to effectively manage the loss of revenue resulting from the sale of Cimerli. The anticipated strong performance of Udenyca, coupled with the successful commercialization of other products in its portfolio, positions Coherus Biosciences to absorb the impact of the Cimerli divestment and maintain a solid financial position.

Promising pipeline data

The promising pipeline data generated by Coherus Biosciences, particularly the positive results from the anti-IL-27 antibody and anti-CCR8 antibody trials, further support the buy rating. These innovative therapies hold significant potential in addressing unmet medical needs and expanding Coherus Biosciences’ market reach. The robust pipeline ensures a continuous flow of new products and underpins the company’s long-term growth prospects.

Risks for Coherus Biosciences

While Coherus Biosciences exhibits strong growth potential, several risks should be considered by investors and stakeholders. These risks encompass potential challenges in financial performance, market penetration, and business development initiatives.

Underperformance in Q1’24 earnings

There is a risk of potential underperformance in Coherus Biosciences’ Q1’24 earnings. Despite the anticipated strong performance of Udenyca, various factors, such as market competition and reimbursement dynamics, can impact sales and revenue. It is crucial for Coherus Biosciences to carefully navigate market challenges and continuously adapt its strategies to mitigate the risk of underperformance.

Lack of market share increase for Udenyca

Although Udenyca has demonstrated considerable market acceptance and growth, there is a risk of limited further market share increase. Market competition and the availability of alternative treatment options can pose challenges to Udenyca’s continued market penetration and adoption. Coherus Biosciences must continue to differentiate Udenyca, invest in targeted marketing efforts, and forge strong relationships with healthcare providers to mitigate this risk.

Potential negative reception of business development initiatives

Coherus Biosciences’ pursuit of business development initiatives carries inherent risks. These initiatives, such as strategic partnerships and acquisitions, can be met with a negative reception by investors and analysts if their perceived value or alignment with Coherus Biosciences’ core business objectives is questioned. It is essential for Coherus Biosciences to carefully evaluate potential opportunities and communicate their strategic rationale effectively to mitigate any potential risks associated with business development initiatives.

In conclusion, Coherus Biosciences’ sale of Cimerli, promising pipeline data, expected performance of Udenyca, and strong financial performance position the company for continued growth and success. Despite potential risks, the buy rating reflects the company’s ability to navigate challenges and deliver value to its shareholders. Coherus Biosciences remains committed to advancing innovative therapies and fulfilling unmet medical needs to improve patient outcomes in the field of biopharmaceuticals.



View all

view all